RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.

Trial Details

NCT ID
NCT06420973
Phase
PHASE2
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • RC48+carboplatin±bevacizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Female subjects aged from 18 to 75 years old;
  • Pathology confirmed the diagnosis of primary epithelial ovarian/fallopian tube/peritoneal carcinoma;
  • Previous treatment lines ≥1 and ≤4, first-line treatment may include maintenance therapy after complete clinical or pathological response;Previousl…
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →